BSH 2023 | MAGNOLIA: zanubrutinib in patients with R/R marginal zone lymphoma

  • Kim Linton

Press/Media: Research

Period24 Apr 2023

Media contributions

1

Media contributions

  • TitleBSH 2023 | MAGNOLIA: zanubrutinib in patients with R/R marginal zone lymphoma
    Degree of recognitionInternational
    Media name/outletVJHaemOnc
    Media typeWeb
    Country/TerritoryUnited Kingdom
    Date24/04/23
    DescriptionKim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, discusses results from the Phase II MAGNOLIA trial (NCT03846427), which evaluated the safety and efficacy of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL). Dr Linton highlights the long-term safety data and high overall response rates (ORR) observed with this agent. When compared to pooled data on patients treated with ibrutinib, zanubrutinib demonstrated lower cardiovascular toxicity and was well tolerated, providing a promising novel therapeutic approach for patients with R/R MZL. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
    Producer/AuthorVJHaemOnc
    URLhttps://www.vjhemonc.com/video/rbnivgrccy0-magnolia-zanubrutinib-in-patients-with-rr-marginal-zone-lymphoma/
    PersonsKim Linton
View all 1
View less

Conference

Title63rd British Society of Haematology Annual Scientific Meeting
Location, Birmingham, United Kingdom
Period23 Apr 2023 → 25 Apr 2023

Related content